Disitamab vedotin

Disitamab vedotin is a HER2-targeted antibody-drug conjugate (ADC) developed by China's RemeGen and licensed worldwide to Seagen in August 2021 for $200M upfront and up to $2.4B in milestones plus high-single-digit to mid-teen royalties [13]. Seagen is now part of Pfizer after the $43B 2023 acquisition [1]. The drug is approved in China (as Aidixi) for HER2-positive gastric cancer and HER2-expressing urothelial cancer [2]. The Phase 3 trial NCT05911295 pairs it with Merck's pembrolizumab against platinum chemotherapy in previously untreated HER2-expressing urothelial cancer [3] - a bid to establish a HER2-selected lane in a market where Pfizer's own enfortumab vedotin plus pembrolizumab has already crushed chemo as standard of care [8].

Disitamab vedotin is approved in China but remains investigational in the US and EU. The Phase 3 (NCT05911295) is active and no longer recruiting, with 412 patients enrolled across HER2 IHC 1+, 2+, and 3+ cohorts [3]. No FDA breakthrough or fast track designation is on file for the urothelial program. The Phase 3 was built on the combined RC48-C005/C009 Phase 2 dataset (Sheng et al. JCO 2023, n=107 HER2 IHC 2+/3+ post-platinum mUC patients): confirmed BIRC ORR 50.5% (95% CI 40.6-60.3), DCR 82.2%, median PFS 5.9 months, median OS 14.2 months. Subgroup ORR was 62.2% in IHC 2+/FISH+ or IHC 3+ patients vs 39.6% in IHC 2+/FISH- patients - a meaningful gradient that the Phase 3's IHC 1+ floor will stress-test [13]. Pfizer is also running a Phase 2 basket (NCT04879329, n=372) of monotherapy and pembrolizumab combinations [4], a Phase 1 in HER2-expressing breast cancer (NCT06966453) [5], and a Phase 2 in previously treated HER2-expressing solid tumors (NCT06003231) [6]. Pfizer has not guided the Phase 3 PFS readout publicly; given enrollment completion, top-line PFS could plausibly read out in 2026, with OS following.

HER2 is a growth-factor receptor that sits on the surface of cells. When cells make too much of it - overexpression - they get stuck telling themselves to grow and divide. Trastuzumab proved decades ago that latching antibodies onto HER2 helps in breast and gastric cancer. Disitamab vedotin takes that idea further: it's an antibody (hertuzumab) that binds HER2, chemically tethered via a cleavable linker to MMAE, a microtubule poison that wrecks the cell's internal scaffolding once the ADC gets pulled inside. Same payload class as Pfizer's enfortumab vedotin (Nectin-4) and Adcetris (CD30). DAR (drug-to-antibody ratio) is 4, versus 8 for T-DXd - fewer payload molecules per antibody, which trades some potency for a different toxicity profile [14]. The mechanistic linchpin for HER2-low activity is bystander killing: MMAE is membrane-permeable after lysosomal cleavage, so drug released inside HER2+ cells diffuses out and kills neighboring HER2-negative tumor cells. That's why the HER2 expression threshold matters less than it does for naked antibodies like trastuzumab - and it's the same logic behind Enhertu's success in HER2-low breast cancer. Bladder tumors don't express HER2 the way HER2-positive breast cancers do - most are IHC 1+ or 2+, not the 3+/amplified pattern. The open question is whether the HER2-low and HER2-intermediate urothelial population is a real responder pool or marketing [7].

NCT05911295 is open-label, randomized 1:1, n=412, comparing disitamab vedotin plus pembrolizumab against investigator's choice platinum-based chemotherapy in untreated locally advanced or metastatic HER2-expressing urothelial cancer (IHC 1+ and above) [3]. Primary endpoint is PFS by blinded independent central review; OS is a key secondary. Sponsor is Seagen (Pfizer). The design has a problem the protocol can't fix: enfortumab vedotin plus pembrolizumab (EV+pembro) became 1L standard of care after EV-302 reported median OS of 31.5 months vs 16.1 for chemo [8]. Beating chemo in 2026 doesn't establish a clinical role - it establishes regulatory eligibility. The real comparison clinicians will make is DV+pembro vs EV+pembro in HER2+ patients, and that comparison isn't being run. Pfizer owns both ADCs, so the commercial strategy may be to position DV+pembro as a HER2-selected option for patients who progress on or can't tolerate EV, rather than displacing it. NCT04879329 may eventually provide Western-population ORR data on DV+pembro before the Phase 3 reads, but no major-congress readout has been disclosed to date.

Our model gives this drug a 33% chance of eventually being approved. It starts from the historical approval rate for Phase 3 drugs in this area-about 48%-then adjusts based on ten facts about the trial and sponsor. The estimate is pushed up by more secondary endpoints than usual, light or open-label blinding, and the sponsor's strong track record of getting drugs approved; it is pushed down by weak or limited earlier-phase results. The remaining factors fall close to average for this stage, so they leave the number roughly where it landed.

Efficacy risk: HER2 IHC 1+/2+ is a fuzzy biomarker. Pathologist concordance for HER2-low scoring has been a documented problem in breast cancer (Tarantino et al. and post-DESTINY-Breast04 reproducibility analyses), and the same noise will affect urothelial subgroups [10]. The RC48-C005/C009 combined Phase 2 already showed a 22-point ORR gap between IHC 2+/FISH+ and IHC 2+/FISH- patients [13] - if the HER2 3+ subgroup carries the Phase 3 effect and 1+/2+ is flat, the broad label Pfizer wants becomes hard to defend. Safety risk: vedotin payloads cause peripheral neuropathy and skin toxicity; in RC48-C005/C009, hypoaesthesia hit 50.5% and leukopenia 49.5% [13]. Combined with pembrolizumab's immune-related adverse events, the regimen has known tolerability friction. Execution risk: trial is fully enrolled, so pace risk is largely behind them. Commercial risk is the biggest one. Even with a positive trial vs chemo, payers and NCCN will compare DV+pembro to EV+pembro, not to chemo. Without a head-to-head or compelling cross-trial advantage, US uptake in 1L is questionable. The likely commercial path is 2L+ post-EV failure, where the addressable population shrinks substantially.

Worth watching, but with realistic expectations. The signal that would matter: PFS hazard ratio under 0.55 in the HER2 3+ subgroup with a clean OS trend. That would justify a HER2-selected niche even against EV+pembro. A diluted overall result with effect concentrated in HER2 3+ and a noisy 1+/2+ subgroup is the more likely outcome. HER2 IHC 3+ is present in ~13% of advanced urothelial samples, and the broader HER2-positive (IHC 3+ or IHC 2+/amplified) population is ~15-16% [11], so a narrow IHC 3+ label addresses a meaningful but limited slice. Pfizer paid $200M upfront and is on the hook for up to $2.4B in milestones plus tiered royalties to RemeGen [13], so the asset has real sunk cost behind it - but Pfizer's 2024 revenue was ~$63B [12], so this is meaningful to the Seagen integration narrative without being company-moving. The bigger Pfizer-Seagen story remains enfortumab vedotin's continued expansion into earlier-line and perioperative bladder cancer, which sets the ceiling for what disitamab vedotin can capture commercially. Check back when Phase 3 PFS top-line drops, expected sometime in 2026.